Eli Raises $1.9 Million CAD in Seed Funding to Develop At-Home Hormone Monitoring Tech

Eli Science Inc. has raised a $1.9 million CAD ($1.5 million USD) seed round to target the historically underserved women’s healthtech market via its saliva-based daily hormone tracking technology.

The round, which was co-led by Hong Kong’s Vectr Ventures and 2048 Ventures, closed in late December 2020. Other investors included Real VenturesTechstarsPanache VenturesRamen VenturesMEDTEQ+, and Steven Arless, who joined Eli Health’s board of directors. To date, the company has raised a total of $2.1 million USD, including prior investments from Techstars and Real Ventures through Techstars Montreal AI accelerator.

Read the original article.

Metadata
Share this article!
We Need Your Help graphic

Make your voice heard!

Sign our petition to urge the government to invest $100M in the Femtech Challenge for the 2025 Budget. Let’s reinforce Canada’s leadership in women’s health and advance gender equality.

Our website uses cookies to ensure you get the best experience. Learn More